Literature DB >> 24840642

Structural evaluation of BTK and PKCδ mediated phosphorylation of MAL at positions Tyr86 and Tyr106.

Rehan Zafar Paracha1, Amjad Ali2, Jamil Ahmad3, Riaz Hussain4, Umar Niazi5, Syed Aun Muhammad6.   

Abstract

A number of diseases including sepsis, rheumatoid arthritis, diabetes, cardiovascular diseases and hyperinflammatory immune disorders have been associated with Toll like receptor (TLR) 2 and TLR4. Endogenous adaptor protein known as MyD88 adapter-like protein (MAL) bind exclusively to the cytosolic portions of TLR2 and TLR4 to initiate downstream signalling. Brutons tyrosine kinase (BTK) and protein kinase C delta (PKCδ) have been implicated to phosphorylate MAL and activate it to initiate downstream signalling. BTK has been associated with phosphorylation at positions Tyr86 and Tyr106, necessary for the activation of MAL but definite residual target of PKCδ in MAL is still to be explored. To produce a better understanding of the functional domains involved in the formation of MAL-kinase complexes, computer-aided studies were used to characterize the protein-protein interactions (PPIs) of phosphorylated BTK and PKCδ with MAL. Docking and physicochemical studies indicated that BTK was involved in close contact with Tyr86 and Tyr106 of MAL whereas PKCδ may phosphorylate Tyr106 only. Moreover, the electrostatics charge distribution of binding interfaces of BTK and PKCδ were distinct but compatible with respective regions of MAL. Our results implicate that position of Tyr86 is specifically phosphorylated by BTK whereas Tyr106 can be phosphorylated by competitive action of both BTK and PKCδ. Additionally, the residues of MAL which are necessary for interaction with TLR2, TLR4, MyD88 and SOCS-1 also play their roles in maintaining interaction with kinases and can be targeted in future to reduce TLR2 and TLR4 induced pathological responses.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Adenosine triphosphate (ATP); BTK; MAL; PKCδ; Protein–protein interactions (PPIs); TIRAP; Tyr106; Tyr86

Mesh:

Substances:

Year:  2014        PMID: 24840642     DOI: 10.1016/j.compbiolchem.2014.04.001

Source DB:  PubMed          Journal:  Comput Biol Chem        ISSN: 1476-9271            Impact factor:   2.877


  6 in total

1.  Solution structure of the TLR adaptor MAL/TIRAP reveals an intact BB loop and supports MAL Cys91 glutathionylation for signaling.

Authors:  Mark M Hughes; Peter Lavrencic; Rebecca C Coll; Thomas Ve; Dylan G Ryan; Niamh C Williams; Deepthi Menon; Ashley Mansell; Philip G Board; Mehdi Mobli; Bostjan Kobe; Luke A J O'Neill
Journal:  Proc Natl Acad Sci U S A       Date:  2017-07-24       Impact factor: 11.205

Review 2.  The role of Bruton's tyrosine kinase in autoimmunity and implications for therapy.

Authors:  Leslie J Crofford; Lindsay E Nyhoff; Jonathan H Sheehan; Peggy L Kendall
Journal:  Expert Rev Clin Immunol       Date:  2016-03-04       Impact factor: 4.473

Review 3.  Molecular mechanisms of regulation of Toll-like receptor signaling.

Authors:  Cynthia A Leifer; Andrei E Medvedev
Journal:  J Leukoc Biol       Date:  2016-06-24       Impact factor: 4.962

4.  Bruton's Tyrosine Kinase Deficiency Inhibits Autoimmune Arthritis in Mice but Fails to Block Immune Complex-Mediated Inflammatory Arthritis.

Authors:  Lindsay E Nyhoff; Bridgette L Barron; Elizabeth M Johnson; Rachel H Bonami; Damian Maseda; Benjamin A Fensterheim; Wei Han; Timothy S Blackwell; Leslie J Crofford; Peggy L Kendall
Journal:  Arthritis Rheumatol       Date:  2016-08       Impact factor: 10.995

5.  TIRAP-mediated activation of p38 MAPK in inflammatory signaling.

Authors:  Sajjan Rajpoot; Ashutosh Kumar; Kam Y J Zhang; Siew Hua Gan; Mirza S Baig
Journal:  Sci Rep       Date:  2022-04-04       Impact factor: 4.379

Review 6.  TIRAP in the Mechanism of Inflammation.

Authors:  Sajjan Rajpoot; Kishore K Wary; Rachel Ibbott; Dongfang Liu; Uzma Saqib; Teresa L M Thurston; Mirza S Baig
Journal:  Front Immunol       Date:  2021-07-08       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.